



Value assessment is an important process to inform national and local deliberations about allocating healthcare resources and achieving the best clinical health and quality-of-life outcomes. As exploration of a systematic, centralized process for review of drugs and other health interventions in the U.S. accelerates, the Innovation and Value Initiative (IVI) believes there is a need to define the principles that must guide future policy and practice. An overarching theme in these principles is defining best practice in the applied use of value assessment: there must be consensus among stakeholder communities on the most effective methods and use cases that are relevant to the U.S. marketplace.

What We Do

IVI seeks to advance the science, practice, and use of value assessment in healthcare to make it more meaningful to those who receive, provide, and pay for care. We envision a U.S. healthcare system that directs resources to the most valuable treatment(s) for every individual patient, to the benefit of all stakeholders.

We achieve this mission and vision by:

- Defining the gaps and limitations in existing value assessment approaches and practices
- Identifying the component elements of value and conducting methods research on how to measure and apply those components to next-generation value assessment
- Improving understanding of how to aggregate those components and incorporate them into value assessment models
- Facilitating application and use of novel value assessment methods to real-world decision contexts
- Building an independent, research-driven organization dedicated to transparency, patient-centeredness, and relevance of value assessment to real-world decisions and experiences of all stakeholders

Leadership Team

Jennifer Bright, MPA

Executive Director

jennifer.bright@thevalueinitiative.org

Rick Chapman, PhD

Chief Science Officer

rick.chapman@thevalueinitiative.org

Mark Linthicum, MPP

Director of Scientific Communications

mark.linthicum@thevalueinitiative.org

Lisa Malecha, MBA

Director of Finance & Operations

lisa.malecha@thevalueinitiative.org

Erica de Fur Malik

Director of Membership & Patient Engagement

erica.malik@thevalueinitiative.org

Melanie Ridley

Director of Development & Partnerships

melanie.ridley@thevalueinitiative.org

Judy Thomas

Operations Manager

judy.thomas@thevalueinitiative.org

Richard Xie, PhD

HEOR Research Manager

richard.xie@thevalueinitiative.org

Featured Projects & Publications

Open-Source Value Project

The Open-Source Value Project is a laboratory for advancing the science and improving the practice of value assessment in the U.S. So far, IVI has developed disease-specific open-source value assessment models for:

- [Rheumatoid Arthritis](#)
- [Non-Small Cell Lung Cancer](#)
- [Major Depressive Disorder](#)

Value Blueprints – An IVI Research Brief Series

IVI's research brief series, Value Blueprints, profiles learnings from the Open-Source Value Project to spark exploration by the health economics and outcomes research community into advancing next-generation value assessment methods.

- [Identifying Patient-Driven Value Elements in Major Depressive Disorder](#) – May 31, 2021
- [Open-Source Modeling for Value Assessment: Promises and Challenges](#) – November 23, 2020
- [Value Assessment in the Context of COVID-19](#) – November 10, 2020
- [Aligning Value Assessment with Treatment in Chronic Disease](#) – December 9, 2019
- [The Impact of Structural Uncertainty on Cost-Effectiveness Estimates](#) – September 3, 2019
- [Enhancing Our Understanding of Long-Term Value: Insurance Value](#) – July 25, 2019
- [Exploring the Implications of the “Value of Hope”](#) – May 20, 2019
- [Patient Insights as the Foundation for Value](#) – May 20, 2019

Selected Peer-Reviewed Publications

Xie RZ, Malik E deFur, Linthicum MT, Bright JL. [Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States](#). *Pharmacoeconomics*. 2021;39(6):631-638.

Linthicum MT, dosReis S, Slejko JF, Mattingly TJ, Bright JL. [The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment](#). *The Patient*. August 28, 2020:1-4.

Incerti D, Thom H, Baio G, Jansen JP. [R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment](#). *Value in Health*. 2019;22(5):575-579.

Jansen JP, Incerti D, Linthicum MT. [Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project](#). *Pharmacoeconomics*. 2019;37(11):1313-1320.

Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP. [A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis](#). *Pharmacoeconomics*. 2019;37(6):829-843.

Jansen JP, Incerti D, Curtis JR. [Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System](#). *Journal of Managed Care & Specialty Pharmacy*. 2019;25(5):518-521.

Informational Webinars

Toward Equity in Value Assessment

- Session 1: [Meaningful Action Toward Health Equity](#) – April 22, 2021
- Session 2: [Methods in Value Assessment that Support Equity](#) – June 24, 2021
- Session 3: [Walking the Talk – How Should Policy Uphold Equity in Value Assessment?](#) – July 14, 2021

IVI Model Scope on Major Depressive Disorder – May 3, 2021

[Recorded Webinar](#) & [Presentation Slides](#)

[Principles for Good Value Assessment](#) – February 25, 2021

[Value Assessment in the Age of COVID-19: Meeting the Challenges](#) – 5-part series in partnership with ISPOR-The Professional Society for Health Economics and Outcomes Research, July - November 2020

[Advancing the Science of Value Assessment: New Open-Source Model for Non-Small Cell Lung Cancer](#) – February 25, 2019

[Modernizing Models for Value Assessment: A Detailed Discussion of the Open-Source IVI-NSCLC Model](#) – February 27, 2019

[Measuring the Value of Health Care Treatments: Time for a New Approach](#) – December 12, 2017

[Creating Open-Source Models for Value Assessment: A Detailed Discussion of the IVI Rheumatoid Arthritis Model](#) – December 14, 2017

Infographics & White Papers

[Partnering with Patients: Principles and Commitments](#)

April 12, 2018

Infographic: [Value Assessment Should Serve Diverse Populations and the Organizations that Provide Their Care](#)

Op-eds, Commentaries & Blog Posts

[How COVID Can Help Us Refocus On The How And Why Of Value Assessment](#)

Darius Lakdawalla, Mark Linthicum, and Charles Phelps
Health Affairs – October 21, 2021

[The Future Of Value Assessment In A Post-Pandemic United States](#)

Donna Cryer
Health Affairs – October 19, 2021

[It's Time to Get Health Care Value Assessment Right](#)

Jennifer Bright and Richard H. Chapman
STAT– April 15, 2021

[A Vision for Patient-Centered Core Impact Sets—A Unifying Approach to Patient Centricity](#)

Eleanor M. Perfetto, Annie Kennedy, and Jennifer Bright
American Journal of Managed Care – March 10, 2021

[Sharpening All the Tools in the Value Assessment Toolbox](#)

Jennifer Bright
American Journal of Managed Care – February 21, 2021

[For Cell and Gene Therapies, MCDA Holds Promise for Improving Equity in Value Assessment](#)
American Journal of Managed Care – July 26, 2020

[The Value of Treating Depression Through the Eyes of Purchasers and Patients](#)
Jennifer Bright
EBN – June 17, 2020

[Covid-19 and Remdesivir: Rethinking How We Measure a Drug's 'Value'](#)
Patricia Deverka, Louis Garrison and Samuel Nussbaum
STAT– June 15, 2020

[Why Accounting for Our Differences Matter in Assessing Drug Value](#)
Jennifer Bright and Amy Miller
American Journal of Managed Care – June 1, 2020

[How to Make Value Assessment More Relevant to Healthcare Decisions](#)
Jennifer Bright
American Journal of Managed Care – February 7, 2020

[We Need to Look Beyond Drugs in Value Assessment](#)
Jennifer Bright
Morning Consult – December 3, 2019

[Drug Pricing and the Broader Quality of Life](#)
Jennifer Bright
The Wall Street Journal – Letter to the Editor – November 14, 2019

[3 Questions to Ask to Improve Your Value Assessment of Benefits](#)
Jennifer Bright
Benefits Pro – October 9, 2019

[Five Steps to Develop Active Learning in Value Assessment](#)
Jennifer Bright
Morning Consult – July 1, 2019

[New Research Brief Series Launched by IVI to Share Learnings from the Open-Source Value Project](#)
Mark Linthicum
Healthcare Economist – May 29, 2019

[You Say Consumer, I Say Patient — Who Is at the Center of It All?](#)
Jennifer Bright
Morning Consult – May 2, 2019

[This is the Real Issue that Should be Driving the National Healthcare Conversation](#)
Thomas Parry and Jennifer Bright
Fierce Healthcare – March 15, 2019

[Value Extends Beyond the Cost of Drugs and Health Care](#)
Jennifer Bright and Mark Linthicum
STAT– March 14, 2019

[Why Crowdsourcing for Value in Healthcare Makes Sense](#)
Mark Linthicum
American Journal of Managed Care – March 7, 2019

[Emancipating Data: Science in the Open Is Key to Understanding Value](#)

Jennifer Bright

Morning Consult – January 3, 2019

[What Path Will Lead to Value Assessment 2.0 in 2019?](#)

Jennifer Bright and Mark Linthicum

American Journal of Managed Care – December 30, 2018

[Patient Perspectives Must Meaningfully Inform Healthcare Value Measurement](#)

Jennifer Bright and Elizabeth Franklin

American Journal of Managed Care – November 23, 2018

[What is a Drug Worth?](#)

Jennifer Bright

The Washington Post – Letter to the Editor – November 16, 2018

[How a 'Waste-Free Formulary' Misses What's Most Important to Employers](#)

Jennifer Bright and Mark Linthicum

Managed Care Magazine – September 27, 2018

[Is One Answer Good Enough for All? Defining Value in Healthcare](#)

Jennifer Bright and Mark Linthicum

American Journal of Managed Care – August 22, 2018

[It's Time to Move to 'Value 2.0' in Healthcare](#)

Mark Linthicum

Fierce Healthcare – July 6, 2018

[Open-Source Tools for Value Assessment: A Promising Approach](#)

Mark Linthicum, Jennifer Bright, and Jason Shafrin.

Journal of Clinical Pathways – 2018

Other Media Appearances

[Find Value: Keys Lost in Dark Alley. Look Under Streetlight?](#)

HealthHats Podcast

September 5, 2021

Podcast interview with Jennifer Bright

[Jennifer Bright: "Collaboration Has to Happen"](#)

Thrive Global

September 14, 2020

Interview with Jennifer Bright

[Identifying and Addressing Multi-Stakeholder Gaps in Value Assessment](#)

Journal of Clinical Pathways

June 12, 2020

Interview with Jennifer Bright & Lou Garrison

[Virtual ISPOR Panel to Examine Next Steps in Value Assessment](#)

American Journal of Managed Care – Virtual ISPOR 2020 Conference

May 17, 2020

Panel Discussion with Lou Garrison and Leah Howard

[Dr Jeroen Jansen Discusses Value-Assessment Questions Posed by Curative Treatments](#)

American Journal of Managed Care

August 14, 2019

Video interview with Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative

[Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population](#)

American Journal of Managed Care

July 14, 2019

Video interview with Devin Incerti, PhD, lead economist, Innovation and Value Initiative.

[Dr Jeroen Jansen on Challenges With Current Approaches to Value Assessment](#)

American Journal of Managed Care

August 1, 2019

Video interview with Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative

[Dr Devin Incerti on the Need for Global Value Assessment to Be Adaptable](#)

American Journal of Managed Care

July 27, 2019

Video interview with Devin Incerti, PhD, lead economist, Innovation and Value Initiative.

[IVI Leads Discussion on QALYs, Value, and Treatment Sequence Modeling in NSCLC](#)

Journal of Clinical Pathways

June 11, 2019

Podcast interview featuring Jennifer Bright, Mark Linthicum, Jeroen Jensen and Devin Incerti

[Heard at ISPOR: Debating the Benefits and Pitfalls of the QALY](#)

American Journal of Managed Care – Managed Care Cast

June 6, 2019

Podcast interview featuring Jennifer Bright and Lou Garrison

[Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment](#)

American Journal of Managed Care

May 22, 2019

Video interview with Devin Incerti, PhD, lead economist, Innovation and Value Initiative

[Debating the Idea of a Middle Ground for QALY in Economic Analysis](#)

Journal of Clinical Pathways

May 20, 2019

Podcast interview featuring Jennifer Bright

[Exploring the New IVI NSCLC Value Modeling Platform](#)

Journal of Clinical Oncology

March 6, 2019

Podcast interview featuring Mark Linthicum

[Value Assessment Platform Must Go Beyond Population Averages](#)

Xtelligent Media – 2018 Value Based Summit

November 1, 2018

Panel discussion featuring Jennifer Bright



Pharmaceutical Value (pValue) applies and tests novel methods for value assessment that encourages stakeholder engagement and promotes value-based decision making. pValue is a recipient of the PhRMA Foundation's Value Assessment Initiative Centers of Excellence Award.

Overview

Traditional measures of value used in cost-effectiveness analyses are not, by definition, fully comprehensive or sufficiently flexible to allow for the inclusion of all criteria that patients, payers, clinicians or other health care stakeholders understand to be important. Multi-criteria decision analysis (MCDA) offers a scientifically rigorous decision-making tool capable of including multiple criteria that are important to stakeholders. MCDA has been applied in a variety of sectors, such as investment banking and environmental management, but applications in U.S. health care decisions have been limited.

MCDA can improve decision making in health care by engaging key stakeholders and capturing and weighing criteria not found in traditional measures of value, for example novelty, severity of disease, quality of evidence and family burden. By encouraging a comprehensive understanding of value, MCDA offers an opportunity to systematically weigh non-traditional aspects of value that fall outside traditional measures.

The University of Colorado's pValue initiative will explore how MCDA can add information on value to improve decision making in health care.

Ongoing Activities

- Review applications of MCDA and where it may show promise for use in coverage and reimbursement decision making
- Educate stakeholder communities on MCDA techniques
- Develop pilot MCDA tools for innovative therapies (e.g. rare diseases and oncology)
- Partner with patient, payer and clinician communities to identify and compare criteria that are important to them
- Test impact of adding MCDA to traditional value assessments, versus traditional value assessment alone, on health care decision making

Key Staff

R. Brett McQueen, PhD
Director
Robert.Mcqueen@cuanschutz.edu

Kavita V. Nair, PhD
Investigator
Kavita.Nair@cuanschutz.edu

Jonathan D. Campbell, PhD
*Former Director and
Steering Committee Member*

Melanie D. Whittington, PhD
*Former Investigator and
pValue collaborator*

Video

- PhRMA Foundation Centers of Excellence: [Spotlight on pValue](#)

Infographics & Primers

- [Multi-Criteria Decision Analysis in Health Care Value Assessment](#)
- [A Clear Path Toward Achieving Value in Health](#)

Recent Publications

- **Stakeholder Perception of Pharmaceutical Value: A Multicriteria Decision-Analysis (MCDA) Educational Case Study for Value Assessment in the United States**
Under construction for re-submission
- **Deriving Patient Experience Value Elements in Rare Disease: A Case Study in Neuromyelitis Optica Spectrum Disorder (NMOSD).**
Under Review
- **Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies.**
PharmacoEconomics. October 2021. (In collaboration with PAVE and CEVA)
- **Patient and Payer Preferences for Additional Value Criteria**
Frontiers in Pharmacology. June 24, 2021
- **Criteria and Scoring Functions Used in the Value Assessment of Rare Disease Therapies: A Systematic Literature Review of Multi-Criteria Decision Analysis Tools and Value Frameworks**
PharmacoEconomics – Open. April 29, 2021
- **How MCDA Can Drive Better Value Assessment**
Voices in Value. April 28, 2021
- **Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment**
PharmacoEconomics. March 24, 2021
- **Using PCORI to Advance Patient-Centered Values**
Fierce Healthcare. November 6, 2019
- **Complementing Coverage and Reimbursement Decisions with Multi-Criteria Decision Analysis**
American Journal of Managed Care. May 27, 2019

Presentations

- **Advancing Stakeholder Engagement in Value Assessment: The Role of Multi-Criteria Decision Analysis (MCDA)**
July, 2021. Virtual Seminar
R. Brett McQueen, PhD and Nick Mendola, MS
Hosted by Merck & Co.

- [Multi-Criteria Decision Analysis: Can it Help Make Value Assessment More Patient Centered?](#)
November 19, 2020. Virtual Webinar
R. Brett McQueen, PhD – Assistant Professor, Co-Investigator, pValue, University of Colorado School of Pharmacy
Hosted in partnership with The National Health Council and The National Pharmaceutical Council
- **The Next Generation of Value Assessment: Including the Patient Voice**
November 12, 2019 Ronald Reagan Building, Washington, D.C.
Jonathan D. Campbell, PhD, Director of pValue
Slide Presentation can be accessed [here](#).

Spotlight on Patient-Centered MCDA: Toward Modified Impact Inventory Tables

To consistently incorporate patient-centeredness in our applications of MCDA, we are using a two-step process and collaboration that engages patients, providers and researchers. First, we plan to educate patients on value assessment and subsequently elicit and prioritize criteria that are of high value to patients when deciding on a treatment. Step one will improve patients' understanding and literacy of value assessment in addition to informing our second step that applies MCDA to real-world treatment scenarios. Second, we will use the patient prioritized criteria from step one to directly inform the assessment of value of real-life treatment case examples through MCDA. Step two will ensure that patient preferences for value criteria around real-life examples are included in the multi-stakeholder MCDA applications. An expanded summary of our process can be found in the in-press publication in *PharmacoEconomics*, titled "[Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment](#)."



The Center for Enhanced Value Assessment

The Center for Enhanced Value Assessment (CEVA) – headquartered within the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center – aims to explore the incorporation of non-traditional elements of value into cost-effective analyses. CEVA is a recipient of the PhRMA Foundation’s Value Assessment Initiative Centers of Excellence Award.

Overview

A key aspect of measuring value is the selection and incorporation of value elements. Traditional measures of value in health care, including quality-adjusted life years (QALYs), do not capture fully patient and societal well-being associated with health such as disease severity, equity of access, or unmet need.

CEVA will expand upon traditional measures of value by exploring measurement of non-traditional elements and their consideration in value assessment processes. These efforts will involve engaging stakeholders – including patients, health insurers, and therapeutic area leaders – to identify important novel and non-standard elements to inform coverage, reimbursement, and access decisions.

Ongoing Activities

- Review how often non-traditional elements of value, such as financial risk protection, productivity, caregiver impact, value of hope, insurance value, and equity are included in published cost-effectiveness analyses
- Characterize the impact of including broader elements of value in areas such as pharmacotherapy for alcohol use disorder, Low-Dose CT for lung cancer screening, bariatric surgery, Non-Hodgkin’s lymphoma, and diabetes prevention
- Characterize patient and other stakeholder views on novel value elements
- Pilot test a user-friendly dashboard for displaying value information alongside cost-per-QALY ratios to demonstrate the importance of non-traditional value elements in cost-effectiveness analyses

Key Staff

Peter Neumann, ScD

Principal Investigator

pneumann@tuftsmedicalcenter.org

Joshua T. Cohen, PhD

Co-Investigator

jcohen@tuftsmedicalcenter.org

Daniel Ollendorf, PhD

Co-Investigator

dollendorf@tuftsmedicalcenter.org

David D. Kim, PhD

Co-Investigator

dkim3@tuftsmedicalcenter.org

Anna Legassie, BA

Co-investigator

alegassie@tuftsmedicalcenter.org

Video

- PhRMA Foundation Centers of Excellence: [Spotlight on CEVA](#)
December 2019

Recent Publications

- Neumann, P.J. [Towards Better Data Dashboards for Cost-Effectiveness Analyses](#). *PhRMA Foundation Blog*. August 13, 2021
- Neumann, P.J. [Toward Better Data Dashboards for US Drug Value Assessments](#). *Value in Health* July 8, 2021.
- Ma S., Kim D.D., Cohen JT. [Measuring “Fearonomic Effects” in Valuing Therapies: An Application to COVID-19 in China](#). *Value in Health*. July 27, 2020.
- Kim D.D., Silver MC., Kunst N., Cohen JT., Ollendorf DA., Neumann PJ. [Perspectives and Costing in Cost-Effectiveness Analysis, 1974-2018](#). *Pharmacoeconomics*. July 22, 2020.
- Kim, D.D., Neumann, P.J. [Value Assessment Research Should Consider Societal Consequences](#). *PhRMA Foundation Blog*. June 2020.
- Kim,D.D., Neumann, P.J. [Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences](#). *Medical Decision Making*. May 2020.
- Miller, G., Neumann, P.J. [Efforts to Measure Value in Health Care: Greater Balance is Needed](#). Concept Paper. Research Consortium for Health Care Value Assessment. July 2019.

Presentations

- **The Next Generation of Value Assessment: Including the Patient Voice**
Peter Neumann, ScD
PhRMA Foundation-National Health Council Conference on New Approaches to Value Assessment
Washington, D.C., November 12, 2019,
Slide Presentation can be accessed [here](#).
- **Perspective in Cost-Effectiveness Analysis: 2nd US Panel’s Deliberations and Practical Guidelines for Analysts**
David D. Kim, PhD
Society for Medical Decision Making 41st Annual North American Meeting
Portland, OR, October 20-23, 2019.
- **Cost-Effective Health Interventions in Global Health: A Comprehensive Analysis of Cost-per-DALY Averted Literature**
David D. Kim, PhD
International Health Economics Association
Basel, Switzerland, July 13-17, 2019.

PAVE PATIENT-DRIVEN
VALUES *in* HEALTHCARE
EVALUATION



Patient-Driven Values in Healthcare Evaluation (PAVE) is a unique collaboration between the University of Maryland School of Pharmacy, the National Health Council, patient community leaders, and payer and industry leaders. The organization is dedicated to developing and advancing new methods to incorporate the patient perspective into value assessment and value-based decision-making. Through this initiative, PAVE is building a diverse and extensive network of partners to build technical expertise in patient-centered health outcomes research, education, and dissemination. PAVE is a recipient of the PhRMA Foundation's Value Assessment Initiative Centers of Excellence Award.

Overview

Patient engagement and perspective is critical to any discussion of value, yet unconventional assessment models often fail to fully capture the patient perspective. It is important for the field of value assessment to evolve to more patient-centric models. PAVE is at the forefront of this movement, developing approaches to value assessment that:

- Solicit meaningful input from patients
- Ensure transparency in methods and decisions
- Develop creative solutions to meet the needs of all health care decision makers

To achieve patient-driven value assessment, it is important to work with patient partners from start to finish. This involves calculating multiple value metrics from different perspectives, and highlighting differences in preferences for treatment and their effects.

Ongoing Activities

- Engage diverse patient communities to identify costs and benefits of treatments that are most important to patients
- Measure patient values and preferences for health-related benefits and risks to incorporate into economic evaluation of treatments
- Test different methodological approaches for patient-driven value assessment in health care interventions and services for individuals
- Perform patient-driven cost-effectiveness analyses using patient-informed value elements
- Educate the patient and research communities on patient-driven value assessment
- Partner with Hispanic community groups to understand patient values that are under-represented in health care evaluation and decision-making

Website

www.pharmacy.umaryland.edu/centers/patient-driven-values-healthcare-evaluation-pave/

Key Staff

Susan dosReis, PhD

Director

sdosreis@rx.umaryland.edu

Julia Slejko, PhD

Co-Director

jslejko@rx.umaryland.edu

Wendy Camelo Castillo, MD, MSc, PhD

Hispanic Patient Engagement Core Lead

wcastillo@rx.umaryland.edu

Joey Mattingly, PhD, PharmD, MBA

Director of Operations

jmattingly@rx.umaryland.edu

C. Daniel Mullins, PhD

Patient Engagement Core Lead

dmullins@rx.umaryland.edu

Eleanor Perfetto, PhD, MS

Education Core Lead

eperfetto@rx.umaryland.edu

Videos, Infographics & Webpages

Video: [PharmacoEconomics Chat: Joseph Mattingly](#)

Video: [Understanding Patient Values in Treatments for Major Depressive Disorders](#)

Video: PhRMA Foundation Centers of Excellence: [Spotlight on PAVE](#)

Video: [What You Need To Know About Hepatitis C](#)

Video: [More Than A Virus: The Impact of Hepatitis C](#)

Infographic: [Patient-Centered Value Assessment: Hepatitis C \(HCV\) treatment](#)

Webpage: [NHC Real World Evidence Classroom](#)

Peer-Reviewed Original Research

Selker H, Cohen T, D'Agostino, Sr. R, Dere W, Nassir Ghaemi S, Honig P, Kaitin K, Kaplan H, Kravitz R, Larholt K, McElwee N, Oye K, Palm M, Perfetto EM, Ramanathan C, Schmid C, Seyfert-Margolis V, Trusheim M, Eichler HG. [A Useful and Sustainable Role for N-of-1 Trials in the Healthcare Ecosystem](#). *Clin Pharmacol Ther*. 2021 Sep 22. DOI: 10.1002/cpt.2425. Epub ahead of print.

Cook N, Livingstone H, Dickson J, Taylor L, Morgan K, Coombes M, Wortley S, Oehrlein E, Vicente-Edo MJ, Waibel F, Liden B. [Development of an international template to support patient submissions in Health Technology Assessments](#). *Int J Technol Assess Health Care*. 2021 Apr 1;37(1):e50. DOI: 10.1017/S0266462321000167

Oehrlein EM, Luo X, Savone M, Lobban T, Kang A, Lee B, Gale R, Schoch S, Perfetto E. [Engaging Patients in Real-World Evidence: An Atrial Fibrillation Patient Advisory Board Case Example](#). *The Patient*. 2021 Mar;14(2):295-300. DOI: 10.1007/s40271-020-00479-8

Slejko JF, Hong YD, Sullivan JL, Reed RM, dosReis S. [Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences](#). *The Patient*. 2021;14(5):569-579. DOI: 10.1007/s40271-021-00495-2

dosReis S, Butler B, Caicedo J, Kennedy A, Hong YD, Zhang C, Slejko JF. [Stakeholder-Engaged Derivation of Patient-Informed Value Elements](#). *The Patient*. 2020;13(5):611-621. DOI: 10.1007/s40271-020-00433-8

Mattingly II TJ, Love BL. [Changes in Cost-effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-effectiveness Analyses](#). *Journal of Managed Care & Specialty Pharmacy*. 2020;26(7):879-886. DOI: 10.18553/jmcp.2020.26.7.879.

Mattingly, T.J., Slejko JF, Onukwugha E, Perfetto EM, Kottlil S, Mullins CD. [Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis](#). *PharmacoEconomics*. 2019;38(2):233-242. DOI: 10.1007/s40273-019-00864-8

Mattingly II TJ, Slejko JF, Perfetto EM, Kottlil S, Mullins CD. [What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism](#). *The Patient*. 2019;12:631-638. DOI: 10.1007/s40271-019-00378-7

Journal Reviews and Commentary

Mattingly II TJ, McQueen RB, Lin PJ. [Contextual considerations and recommendations for estimating the value of Alzheimer's disease therapies](#). *PharmacoEconomics*. 2021;39(10):1101-1107.

Mattingly II TJ, Heil EL. [The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface](#). *Clinical Infectious Diseases*. 2021;72(6):939-941.

Mattingly II TJ, Slejko JF, Oehrlein EM, Perfetto E. [Nudging Health Economists: A Process for Systematic Identification of Patient-Centered Outcomes for Inclusion in Value Assessment](#). *ISPOR's Value & Outcomes Spotlight*. Vol. 7. No. S2. September 2021.

Perfetto, E.M., Schoch, S., Oehrlein, E.M. [Tools for Compensating Patients for Their Patient-Engagement Activities](#). *ISPOR's Value & Outcomes Spotlight*. Vol. 7. No. 3. June, 2021.

McQueen RB, Slejko JF. [Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment](#). *PharmacoEconomics*. 2021;39(4):379-382. DOI:/10.1007/s40273-021-01017-6.

Medeiros M, Love TR, Slobogean GP, Sprague S, Perfetto EM, O'Hara NN, Mullins CD. [Patient and stakeholder engagement learnings: PREP-IT as a case study](#). *J Comp Eff Res*. 2021;10(6):439-442. DOI: 10.2217/ce-2020-0266.

Linthicum MT, dosReis S, Slejko JF, Mattingly TJ, Bright JL. [The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment](#). *The Patient*. 2021;14(4):381-384.

Desai B, Mattingly II TJ, van den Broek R, Pham N, Frailer M, Yang J, Perfetto EM. [Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment](#). *Value in Health*. 2020;23(6):689-696. DOI: 10.1016/j.jval.2020.01.014.

Mattingly II TJ, Love BL, Khokhar B. [Real World Cost-of-Illness Evidence in Hepatitis C Virus: A Systematic Review](#). *PharmacoEconomics*. 2020;38(9):927-939.

Mattingly II TJ. [The Economics of Drug Allergy](#). *Current Opinion in Allergy & Clinical Immunology*. 2020;20(4):395-400. DOI: 10.1097/ACI.0000000000000651.

Mattingly II TJ, Shere-Wolfe K. [Clinical and Economic Outcomes Evaluated in Lyme Disease: A Systematic Review](#). *Parasites & Vectors*. 2020;13:34. DOI: 0.1186/s13071-020-04214-y.

Harrington RL, Hanna ML, Oehrlein EM, et al. [Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group](#). *Value Health*. 2020;23(6):677-688. DOI:10.1016/j.jval.2020.01.019.

Mattingly II TJ. [Elimination of Hepatitis C Virus Infection in Canada is Achievable, But is the Rest of the World Ready to Join in This Effort?](#) *JAMA Network Open*. 2020;3(5):e204355. DOI:10.1001/jamanetworkopen.2020.

Slejko, J.F., Mattingly, T.J., Mullins C.D., Perfetto E.M., dosReis, S. [The Future of Patient-Driven Healthcare Evaluation: The Patient-Informed Reference Case](#). *Value in Health*. 2019 May;22(5):545-548. DOI: 10.1016/j.jval.2019.02.003.

Op-eds, Editorials, Reports & Blog Posts

National Health Council and National Alliance of Healthcare Purchaser Coalitions. [A Dialogue on Value Assessment that Meets the Needs of Patients and Employers](#). Washington, DC, June 2021.

Oehrlein EM, Perfetto EM, Schoch S, et al. [Patient-Centered Real-World Evidence: Methods Recommendations from an Evidence-Based Consensus Process](#). National Health Council, Washington DC, May 2021.

Perfetto E. [Project Update: Patient-Centered Core Impact Sets \(PC-CIS\)](#). National Health Council, Washington, DC, June 10, 2021.

dosReis, S, Linthicum, M, de Fur Malik, E, Slejko, JF, Xie, R. [Identifying Patient-Driven Value Elements in Major Depressive Disorder](#). Innovation and Value Initiative (IVI) Value Blueprint. May 31, 2021.

dosReis, S. [The Patient Perspective Approach Should Guide Value Assessments of COVID-19 Vaccines](#). *Medium*. May 18, 2021

Mattingly, TJ. [Centering the Patient Perspective in Hepatitis C Treatment Evaluation](#). *Voices in Value*. May 14, 2021

Perfetto E, Kennedy A, Bright J. Contributor: [A Vision for Patient-Centered Core Impact Sets—A Unifying Approach to Patient Centricity](#). *American Journal of Managed Care*. March 10, 2021.

Camelo Castillo, W. [Racial and Ethnic Disparities in Health Care are Found in the Missing Patient Voice](#). *Medium*. November 10, 2020

Mattingly, TJ, McQueen RB. [Using PCORI to Advance Patient-Centered Values](#). *Fierce Healthcare*. November 6, 2019

dosReis, S. [Making the Patient Voice Matter In Value Assessment](#). *Managed Care Magazine*. September 3, 2019.

Mattingly, TJ, Slejko, JF, Perfetto, EM, dosReis, S. [Putting Our Guard Down: Engaging Multiple Stakeholders to Define Value in Healthcare](#). *Health Affairs Blog*. January 28, 2019.

Conference Presentations

Podium Presentations:

Patient-Informed Value Elements Influencing Preferences for the Treatment of Major Depressive Disorder Among Adults. dosReis, S., Bozzi, L., Butler, B., Xie, R.Z., Chapman, R.H., Bright, J., Malik, E., Slejko, J.F. Society for Medical Decision Making (SMDM) Virtual Annual Meeting. October 18, 2021.

Considering the Full Range of Outcomes in PCORI-Funded Research. Perfetto EM. PCORI Virtual Annual Meeting. October 4, 2021.

Eliciting Value Elements for a Patient-Driven Value Assessment. Hong YD, Zhang C, Slejko JF, dosReis S. *Value in Health*. May 2019;22(Suppl. 2):S37.

Poster Presentations:

Identification of Model Attributes for Patient-Centered Value Assessment of Treatments for Major Depressive Disorder (MDD). Slejko JF, Mattingly TJ, Wilson A, Xie RZ, Chapman RH, dosReis S. Society for Medical Decision Making (SMDM) Virtual Annual Meeting. October 20, 2021.

Eliciting Patient Informed Value Elements for Economic Evaluation of COPD Treatment. Slejko JF, Hong YD, Bozzi L, dosReis S. Respiratory Effectiveness Group (REG) Virtual Summit. March 18-20, 2021

A Patient-Informed Approach to Develop a Discrete Choice Experiment for COPD Treatment. Slejko JF, Hong YD, Bozzi LM, dosReis S. Virtual ISPOR 2020. May 18-22, 2020. *Value in Health*. 2020;23:S360.

Aligning COPD Outcomes with Patient-Informed Value Element Domains for Use in Economic Evaluations. Slejko JF, Gray C, Hong YD, Rueda JD, Zhang C, dosReis S. *Value in Health*. 2019;22(Suppl. 2):S351.

Identifying COPD Patient-Informed Value Elements in Economic Evaluations: A Systematic Review. Gray C, Slejko JF. *Value in Health*. 2019;22(Suppl. 2):S361.

Workshops/Issue Panels:

Introduction to Patient Engagement in Medical Product Research. Martin Nguyen A, McBurney R, Oehrlein EM, Schrandt S, ISPOR Short Course. October 20-21, 2021.

RWE Perspectives: Diversity in Data, Devices and Patient Populations. Siami S, Aguel F, Oehrlein E, Peiris V, Salama M, NEST RWE². September 21, 2021.

Putting Patients At The Heart: Resources and Good Practice For Patient Involvement in HTA. Oehrlein E, HTAi Annual Meeting. June 20, 2021.

Patient Participation At The Organizational Level in HTA. Discussion Leaders: Berglas S, Livingstone H, Oehrlein E, Coombs M, Nabarette H, HTAi Annual Meeting. June 20, 2021.

Measuring Relative Value: Advancing Patient-Centered Methods in Value Assessment. Kamal-Bahl S, McQueen B, Slejko JF, Neumann PJ, Academy Health Annual Research Meeting. June 16, 2021.

Addressing Health Inequity in The U.S.: How Can Value Assessment (VA) Contribute to More Equitable Healthcare Resource Allocation? Discussion Leaders: dosReis S, Garrison LP, Kowal S, Xie R, Virtual ISPOR 2021 (Pre-Release/On-Demand).

Advancing Employer Engagement on Value Assessment. Oehrlein EM, Rehayem M, Westrich K, Bright J, Virtual ISPOR 2021.

Qualitative and Quantitative Applications of Incorporating the Patient Voice into Value Assessments. Oehrlein EM, McQueen R, Whittington M, Slejko J, Virtual ISPOR 2021 Workshop.

An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation. dosReis S, Slejko JF, Lakdawalla DN, Willke RJ. ISPOR 2019 Workshop.

Invited Seminars and Webinars

Julia Slejko, PhD (PAVE), R. Brett McQueen, PhD (pValue), Peter Neumann, ScD (CEVA), Jennifer Bright, MPA (IVI), Annie Kennedy (EveryLife Foundation for Rare Diseases), LaTasha H. Lee, PhD, MPH (National Minority Quality Forum), Kenneth "Kenny" Mendez (Asthma and Allergy Foundation of America).

"Spotlight on Current and Emerging Approaches and Methods to Enhance Patient-Centricity and Inclusive Patient Engagement in Value Assessment."

PhRMA Foundation webinar series on Advancing Patient-Centered Outcomes and Impacts in Value Assessment.
November 12, 2021.

Susan dosReis, Julia Slejko, Alejandro Amill-Rosario.

"Emerging Health Technology Assessment Methods and Evidence Generation on Patient-Driven Values in Healthcare Services".

Enhancing Health Care Value Through Data, Measurement and Evaluation of Services and Procedures.

Research Consortium for Health Care Value Assessment. November 3, 2021

Eleanor Perfetto, PhD (PAVE/NHC)

"Value Based Care: Look Ahead Roundtable"

Virtual presentation, Cancer Support Community.

October 14, 2021.

Elisabeth Oehrlein, PhD (PAVE/NHC), Lori Frank, PhD (RAND Corporation), Louis P. Garrison, Jr., PhD (University of Washington), Charlene Son Rigby (RARE-X), Bari Talente (National Multiple Sclerosis Society), Sean Tunis, MD, MSc (Rubix Health), Ashley Valentine, MRes, MPH (Sick Cells).

"History and Current Landscape of Patient-Centricity and Patient-Centered Outcomes/Impacts in Value Assessment"

PhRMA Foundation webinar series on Advancing Patient-Centered Outcomes and Impacts in Value Assessment.

September 17, 2021.

Julia Slejko, PhD (PAVE)

'Patient-Centered Value Assessment'

Virtual Seminar, University of Oxford Health Economics Research Centre (HERC).

September 15, 2021

Elisabeth Oehrlein, PhD (PAVE/NHC)

BIO Patient Advocacy Coffee Chat on Value Assessment.

September 8, 2021.

Eleanor Perfetto, PhD (PAVE/NHC), Elisabeth Oehrlein, PhD (PAVE/NHC)

"What Are Patient-Centered Outcomes and Why Aren't All Health Outcomes Considered "Patient Centered?""

National Health Council.

August 11, 2021.

Rachele Hendricks-Sturup, DHSc (Duke-Margolis Center for Health Policy), Elisabeth Oehrlein, PhD (PAVE/NHC), Mehmet Burcu, PhD (Merck & Co.).

"Patient-Centered Real-World Evidence: Consensus Recommendations & Use Cases"

National Health Council.

July 30, 2021.

Julia Slejko, PhD (PAVE)

"Eliciting, Prioritizing and Quantifying Value Elements for COPD"

Virtual Seminar, University of Illinois Chicago Population Health Sciences Program and Breathe Chicago Center.

June 17, 2021.

Susan dosReis, PhD (PAVE), Jennifer Bright, MPA (IVI), Yvette Venable (ICER).
Value Assessment and Women. Society for Women's Health Research.
Virtual Policy Council Meeting.
June 3, 2020.

Susan dosReis, PhD (PAVE), George Miller, PhD (RC-HCVA), Jon Campbell, PhD (pValue), Peter Neumann, ScD (CEVA)
Moderator: Sachin Kamal-Bahl, PhD (COVIA Health Solutions)
"Grant Recipients Highlight New Approaches to Value Assessment"
The Next Generation of Value Assessment: Including the Patients Voice Series by PhRMA Foundation & National Health Council.
November 12, 2019, Washington, D.C.

Lisa Bo Feng, DrPH (Cystic Fibrosis Foundation), Susan dosReis, PhD (PAVE), Josh Seidman, PhD (Avalere Health), David Steinhorn,
MD (Children's National Medical Center)
Moderator: Jennifer Bright, MPA (Momentum Health Strategies)
"Navigating the Frontiers of Innovation and Value: The Value of the Patients Voice"
Alliance for Health Policy 2019 Solving Health Signature Series.
November 6, 2019, Washington, D.C.

Julia Slejko, PhD (PAVE), Jamie Sullivan (COPD Foundation)
Moderator: Eleanor Perfetto, PhD (PAVE)
"Partners' Perspectives on the Value of a Patient-Researcher Partnership"
National Health Council 2019 Science of Patient Engagement Symposium.
October 28-29, 2019. Washington, D.C.

Julia Slejko, PhD (PAVE)
"Value Assessments and the Role of the Patient Voice"
COPD Foundation IMPACT COPD Workshop.
June 18, 2019, Washington, D.C.